The U.S. Food and Drug Administration authorized a higher number of medical devices in the first half of 2026 compared with the same period in 2025. Review timelines for original premarket approvals lengthened substantially during this period. The trend emerges as the agency prepares for a public meeting on August 5, 2026, regarding future medical device user fee commitments.
In Silver Spring, Maryland, the FDA’s Center for Devices and Radiological Health reported increased device authorizations through June 2026. Analysts from BTIG noted that original premarket approvals rose while average review durations extended. This development arrives months after the Quality Management System Regulation took effect on February 2, 2026, aligning U.S. requirements more closely with ISO 13485:2016.
The higher authorization volume reflects ongoing demand for innovative medical devices across diagnostics, therapeutics, and digital health. At the same time, longer review cycles have drawn attention from manufacturers seeking predictable pathways to market.
FDA data for the first half of 2026 showed more total device authorizations than the corresponding period a year earlier. Original premarket approvals specifically increased, with 23 devices cleared through that pathway by the end of June—an increase of 10 from the prior year.
A July 2026 BTIG report highlighted that review times for these original approvals grew substantially longer. Certain complex submissions contributed to the extended timelines. The agency continued processing 510(k) clearances and other pathways alongside the premarket approval caseload.
On the regulatory front, the FDA published a draft commitments letter for the Medical Device User Fee Act covering fiscal years 2028 through 2032. A public meeting is scheduled for August 5, 2026, in the Washington, D.C., area. Stakeholders may submit written comments through August 7, 2026.
The Quality Management System Regulation, effective since February 2, 2026, replaced prior quality system requirements under 21 CFR Part 820. It incorporates ISO 13485:2016 by reference and updates inspection approaches for medical device manufacturers.
Recent agency actions also included device corrections and recalls. Examples from late July 2026 involved Resmed Astral ventilators and certain catheter introducer kits from Abiomed.
Longer review times can delay patient access to new medical devices and increase development costs for manufacturers. Companies may need to adjust resource planning and clinical evidence strategies to account for extended FDA evaluation periods.
The rise in overall authorizations signals continued innovation in the medical device sector. Higher volumes may ease some market bottlenecks once reviews conclude. Alignment with international standards through the Quality Management System Regulation aims to reduce regulatory divergence for global companies.
For healthcare providers and patients in the United States, the net effect depends on the balance between faster eventual availability of more devices and temporary delays in specific high-complexity products. Industry groups are monitoring whether the upcoming user fee negotiations will address review efficiency.
The FDA will host the public meeting on the MDUFA draft commitments letter on August 5, 2026. Feedback from that session and the concurrent comment period will help shape performance goals and fee structures for the next user fee cycle.
Manufacturers are expected to adapt quality systems fully to the new regulation and prepare submissions that account for current review durations. Further guidance documents on the FDA’s 2026 agenda may provide additional clarity on lifecycle management and marketing submission recommendations.
Observers will track second-half 2026 authorization and timeline data to determine whether the first-half patterns persist. Any adjustments emerging from the August discussions could influence device development timelines into 2027 and beyond.
FAQ
How many medical devices did the FDA authorize in the first half of 2026?
The agency authorized more devices overall than in the first half of 2025. Original premarket approvals reached 23 through June, up by 10 from the prior year.
Why are medical device review times longer in 2026?
Analysts attribute the increase primarily to a rise in complex submissions. Specific outliers contributed to higher average review durations for original premarket approvals.
What is the Quality Management System Regulation?
Effective February 2, 2026, it updates U.S. quality system requirements for medical devices and incorporates ISO 13485:2016 by reference to promote global harmonization.
When is the next major FDA medical device public meeting?
A public meeting on the draft MDUFA commitments letter is scheduled for August 5, 2026. Written comments are due by August 7, 2026.
How might longer reviews affect patients?
Extended timelines can delay availability of certain new devices. Higher overall authorization volumes may eventually expand treatment options once reviews are completed.